On March 26, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) released its 2025 annual results. Driven by the in-depth advancement of its comprehensive innovation and development strategy and the rapid volume growth of innovative products launched intensively over the past three years, the company has delivered impressive results of double-digit growth in both revenue and net profit for four consecutive reporting periods.

On March 22, the China Development Forum 2026 Annual Conference opened in Beijing. Qiang Li, a member of the Standing Committee of the Political Bureau of the CPC Central Committee and Premier of the State Council, attended the opening ceremony and delivered a keynote speech.

On March 23, MSCI (Morgan Stanley Capital International), an internationally authoritative index provider, released its latest Environmental, Social, and Governance (ESG) rating results.

Recently, TQB6457 for injection, a Class 1 innovative drug submitted by CTTQ Pharma, a core member company of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), has officially received implied permission for clinical trials from the Center for Drug Evaluation (CDE), NMPA, for the treatment of advanced malignant neoplasms.

Recently, the results of the Phase II clinical trial (PACER-II) of TQC3721 suspension, a PDE3/4 inhibitor independently developed by CTTQ Pharma, a core member company of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), for Chronic Obstructive Pulmonary Disease (COPD), were officially published in the renowned international respiratory journal CHEST.

On March 17, the 2026 Yabuli Entrepreneurs Forum was held in Yabuli, Heilongjiang. With the theme Confidence, Opportunity, and a New Chapter, the forum brought together entrepreneurs from all sectors to discuss new paths for development.

Recently, TRD221 for injection, a Class 1 innovative drug developed by Beijing Tide Pharmaceutical, a core member company of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), in collaboration with the Institute of Materia Medica, Chinese Academy of Medical Sciences, has received implied permission for clinical trials from the Center for Drug Evaluation (CDE), NMPA, for the proposed treatment of osteoarthritis. TRD221 is a First-in-Class (FIC) complex polysaccharide drug with a novel structure, expected to offer a new treatment option for over 100 million osteoarthritis patients in China.

On March 14, the 2026 Shanghai Global Investment Promotion Conference opened with a main promotion event at the Shanghai East International Business Cooperation Zone.

On March 12, CTTQ Pharma, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced that the Phase III clinical study of its independently developed Class 1 innovative drug, TQB3454 tablets, for the treatment of advanced bile duct cancer with IDH1 mutations, has completed its pre-specified interim analysis.

On March 9, the 2026 Forbes China list of Top 100 Outstanding Businesswomen was officially released, and the Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK) was once again included for her profound influence in the field of pharmaceutical innovation.